1. Merck leaps into COVID vaccine race — Evofem Biosciences gets FDA approval for new non-hormonal contraceptive — Sanofi sells $13 billion stake in Regeneron — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

All Braeburn Sales Reps fired on 1/22/18 !!!

Discussion in 'Braeburn Pharmaceuticals' started by anonymous, Jan 23, 2018 at 11:38 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Base for Reps starting at 130k.
     

  2. anonymous

    anonymous Guest


    Nah, I heard it was one fiddy. $$$
     
  3. anonymous

    anonymous Guest

    Titan says they want the rights to probuphine back.
     
  4. anonymous

    anonymous Guest


    That was their starting point in negotiation.
     
  5. anonymous

    anonymous Guest

    Well, Titan is dumb enough to trust Braeburn that's for sure. Bottom line, the REMS and insurance pre-approvals make probuphine impossible to sell. Maybe they'll do better with injectables
     
  6. anonymous

    anonymous Guest

    Y’all mf’ers just sitting here wishing upon a star. You think Indivior is run poorly. They trying to buy relationships with a weak ass product. Gonna make 125 for about 5 months. Lol
     
  7. anonymous

    anonymous Guest


    You’re right. At the moment, we haven’t got anything better to do.
     
  8. anonymous

    anonymous Guest

    Can't wait to outsell Indivior.
     
  9. anonymous

    anonymous Guest

    Good luck with that. They still have the Film, which is going to bring in solid cash flow. You have, what, $110 million from investors? If they haven’t pulled out. Indivior makes that in half a quarter. You’re banking on a product that is already 2nd to the party against a giant. I have no skin in the game, but looking at it from an investor’s point of view, they’re going to be hard to beat. They have the cash flow, history, and relationships you don’t. Every single time a competitor has tried to take them on, they have lost. Look at BDSI and Orexo, they’re barely making it. I hope you succeed, honestly, because more treatment options is good. But don’t get cocky when you aren’t on the market yet, and won’t be for several more months.
     
  10. anonymous

    anonymous Guest

    Good luck with that. They still have the Film, which is going to bring in solid cash flow. You have, what, $110 million from investors? If they haven’t pulled out. Indivior makes that in half a quarter. You’re banking on a product that is already 2nd to the party against a giant. I have no skin in the game, but looking at it from an investor’s point of view, they’re going to be hard to beat. They have the cash flow, history, and relationships you don’t. Every single time a competitor has tried to take them on, they have lost. Look at BDSI and Orexo, they’re barely making it. I hope you succeed, honestly, because more treatment options is good. But don’t get cocky when you aren’t on the market yet, and won’t be for several more months.
     
  11. anonymous

    anonymous Guest

    What she said